- Australia
- /
- Healthtech
- /
- ASX:ONE
Oneview Healthcare Full Year 2023 Earnings: €0.02 loss per share (vs €0.021 loss in FY 2022)
Oneview Healthcare (ASX:ONE) Full Year 2023 Results
Key Financial Results
- Revenue: €9.40m (up 5.3% from FY 2022).
- Net loss: €8.93m (loss narrowed by 18% from FY 2022).
- €0.02 loss per share (improved from €0.021 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Oneview Healthcare Earnings Insights
Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are up 13% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Oneview Healthcare that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:ONE
Oneview Healthcare
Develops and sells software and related consultancy services for the healthcare sector in Ireland, the United States, Australia, Asia, and the Middle East.
Flawless balance sheet and slightly overvalued.